Repositorio Dspace

Listar02.01.01. Investigación y comunicación científica por tema "Natalizumab/therapeutic use"

Listar02.01.01. Investigación y comunicación científica por tema "Natalizumab/therapeutic use"

Ordenar por:Orden:Resultados:

  • Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study 
    Meca-Lallana, José-Eustasio; Ayuso, Teresa; Martínez-Yélamos, Sergio; Durán, Carmen; Contreras-Martín, Yessica; Herrera-Navarro, Nicolás; Pérez-Sempere, Ángel; Álvarez-Cermeno, José-C; Millán-Pascual, Jorge; Meca-Lallana, Virginia; Romero-Sevilla, Raúl; Ricart, Javier (KARGER, 2020-05)
    BACKGROUND: There is a lack of head-to-head studies comparing the efficacy of fingolimod (FIN) and natalizumab (NTZ) as second-line therapy for relapsing-remitting multiple sclerosis (RRMS). METHODS: Multicenter, observational ...
  • Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study 
    Barrero, Francisco; Mallada-Frechin, Javier; Martínez-Gines, María-Luisa; Eugenia-Marzo, María; Meca-Lallana, Virginia; Izquierdo, Guillermo; Ara, José-Ramón; Oreja-Guevara, Celia; Meca-Lallana, José-Eustasio; Forero, Lucía; Sánchez-Veram, Irene; Moreno, María-José (PUBLIC LIBRARY SCIENCE, 2020-04-02)
    PURPOSE: The objective of this study was to characterize the demographic and clinical profile of RRMS patients receiving fingolimod in Spain, and to evaluate drug effectiveness and safety in clinical practice. METHODS: ...

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta